Red Cell Distribution Width as an Independent Predictor of Exercise Intolerance and Ventilatory Inefficiency in Patients with Chronic Heart Failure

Sung-Jin Hong,¹* Jong-Chan Youn,¹* Jaewon Oh,¹ Namki Hong,¹ Hye Sun Lee,² Sungha Park,¹,³ Sang-Hak Lee,¹,³ Donghoon Choi,¹,³ and Seok-Min Kang¹,³

¹Division of Cardiology, Severance Cardiovascular Hospital and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul; ²Department of Biostatistics, Yonsei University College of Medicine, Seoul; ³Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.

Purpose: Peak oxygen uptake (peak VO₂) and ventilatory inefficiency (VE/VCO₂ slope) have proven to be strong prognostic markers in patients with chronic heart failure (CHF). Recently increased red cell distribution width (RDW) has emerged as an additional predictor of poor outcome in CHF. We sought to evaluate the relationship between RDW and cardiopulmonary exercise test (CPET) parameters in CHF patients and healthy controls.

Materials and Methods: 85 ambulatory CHF patients (68 men, 54±10 years) and 107 healthy controls, who underwent a symptom-limited CPET on a treadmill according to the modified Bruce ramp protocol, were enrolled. CHF patients and healthy controls were divided into RDW tertile groups and laboratory, echocardiographic, and CPET results were analyzed.

Results: For patients with CHF, compared with patients in the lowest RDW tertile, those in the highest tertile had lower peak VO₂ (22 mL/kg/min vs. 28 mL/kg/min, \( p < 0.001 \)) and higher VE/VCO₂ slope (31 vs. 25, \( p = 0.004 \)). Multivariate regression analysis revealed RDW to be an independent predictor for peak VO₂ (\( \beta = -0.247, p = 0.001 \)) and higher VE/VCO₂ slope (\( \beta = 0.366, p = 0.004 \)). The optimal cutoff value of RDW for predicting peak VO₂ ≤20 mL/kg/min and VE/VCO₂ slope ≥34 was 13.6% (sensitivity 53%, specificity 89%) and 13.4% (sensitivity 75%, specificity 82%), respectively. In contrast, for healthy controls, RDW was not related to both peak VO₂ and VE/VCO₂ slope. Conclusion: Higher RDW is independently related to peak VO₂ and VE/VCO₂ slope only in patients with CHF. RDW assessment, an inexpensive and simple method, might help predict functional capacity and ventilatory efficiency in these patients.

Key Words: Cardiopulmonary exercise test, heart failure, red cell distribution width

INTRODUCTION

The cardiopulmonary exercise test (CPET) is an important clinical tool used to de-
termine the severity and prognosis of heart failure (HF). Among the various CPET parameters, peak oxygen uptake (peak VO2) and ventilatory response to exercise (VE/VCO2 slope), measured by the slope of the increase in ventilation with respect to CO2 output, have been demonstrated to have a prognostic significance as indices of exercise capacity and ventilatory efficiency.1-3

Red cell distribution width (RDW), a measure of size variability among red blood cells, has been found to be a prognostic marker in patients with HF and acute dyspnea.4-8 Although the mechanism for the association between increased RDW and poor prognosis in HF is not clearly elucidated, chronic inflammation, kidney dysfunction, hepatic congestion, and nutritional deficiencies in HF were suggested for the underlying mechanism for the increased RDW.9-12 Therefore, we hypothesized that a higher RDW, which represents an increased severity of and an adverse prognosis for HF, would be related to exercise intolerance or ventilatory inefficiency, the measurements reflecting the severity of HF, especially in patients with chronic HF (CHF). In contrast, for control subjects who have much less conditions for increased RDW, it might be less related to exercise intolerance or ventilatory inefficiency compared to those with CHF. Therefore, the present study evaluated the relationship between RDW and CPET parameters, especially peak VO2 and VE/VCO2 slope, in patients with CHF and in healthy controls.

MATERIALS AND METHODS

Subjects
We retrospectively identified 1038 patients who underwent CPET between August 2011 and June 2012. Among them, we consecutively enrolled 120 CHF patients all in stable clinical condition with regard to symptoms and therapy for at least 3 months and with a left ventricular ejection fraction (LVEF) <55%. Patients with known hematologic diseases, neoplastic metastases to bone marrow, pregnancy, severe arthritis, inflammatory bowel diseases, chronic obstructive pulmonary disease, transfusion, iron replacement therapy (which can increase plasma RDW levels), and other extracellular fluid increasing diseases (e.g., hypothyroidism and liver cirrhosis) were excluded. A total of 35 patients without laboratory test results within 3 months from the CPET examinations were excluded, and the final analysis included 85 CHF patients. Also, we analyzed 107 healthy controls that underwent CPET in the same periods. They did not have any cardiovascular risk factors such as hypertension, diabetes or dyslipidemia.

The institutional review board of Yonsei University College of Medicine approved the study protocol.

Laboratory and echocardiographic measurements
Blood samples were obtained after an 8-h overnight fast by venipuncture into plain and EDTA tubes. Patients had venous blood collected for the measurement of routine blood chemistry. Using the Advia 2120i automated analyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA), hematologic variables such as hemoglobin, hematocrit, mean corpuscular volume, and RDW were measured. The reference range for RDW in our laboratory was 11.5-14.5%. Renal function was determined by estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula.13

Two-dimensional echocardiographic findings were obtained. LVEF was measured using the modified Quinones method.14 In patients who had regional wall motion abnormalities, LVEF was calculated by the biplane Simpson’s method using apical four and two-chamber views.15 Left atrial volume index (LAVI) was measured using the prolate ellipsoid method.16 Pulsed-wave Doppler echocardiography of mitral inflow and tissue Doppler imaging from the apical four-chamber view with 2- to 5-mm sample volumes placed at the septal corner of the mitral annulus were used to determine the peak velocity of early diastolic filling (E), late filling (A), peak systolic velocity (S’) and early diastolic velocity (E’).17 Systolic pulmonary artery pressure was estimated from tricuspid regurgitation velocity by adding the right atrial pressure.

Cardiopulmonary exercise testing
A symptom-limited CPET was performed on a treadmill according to the modified Bruce ramp protocol. Patients were strongly encouraged to achieve a peak respiratory exchange ratio (RER) >1.10. Expired gases were collected continuously throughout exercise and analyzed for ventilator volume, oxygen (O2) content, and carbon dioxide (CO2) content using a calibrated metabolic cart (Quark CPET, COSMED, Chicago, IL, USA). Expired gases were reported every 15 s. During the exercise test, monitoring consisted of continuous 12-lead electrocardiography, manual blood pressure measurements every stage, and heart rate (HR) recordings every stage via the electrocardiogram.
CPET was terminated according to following criteria; patient request, ventricular tachycardia, ≥2 mm of horizontal or down-sloping ST segment depression or a drop in systolic blood pressure ≥20 mm/Hg during exercise. A qualified exercise physiologist with physician supervision conducted each test.

The following variables were derived from the CPET results: peak oxygen consumption (peak VO$_2$); peak RER, defined by the ratio of CO$_2$ production to O$_2$ consumption at peak effort; VE/VCO$_2$ slope, defined as the slope of the increase in peak ventilation/increase in CO$_2$ production throughout exercise. Peak RER had the highest 30-s averaged value during the last stage of the test. Heart rate reserve (HRR) was defined as the difference between basal and peak HR.

**Statistical analysis**

Continuous variables are expressed as mean±standard deviation and categorical variables as numbers and percentages. RDW values were treated as categorical variables in tertile groups because RDW was not normally distributed even after a log transformation. To compare baseline variables among RDW tertile groups, we used ANOVA for continuous variables and the chi-square test for categorical variables. Simple linear regression analysis was performed to assess the relationship between CPET parameters and other clinical, laboratory, and echocardiographic parameters. The independent predictors of peak VO$_2$ and VE/VCO$_2$ slope were assessed by a multiple linear regression, performed on the clinical and laboratory covariates identified in previous published studies as affecting to peak VO$_2$ and VE/VCO$_2$ slope. All analyses were performed for patients with CHF and for healthy controls.

To test the statistical significance of adding RDW to other clinical and laboratory parameters for prediction of outcomes, we compared a model with RDW (full model) with a model without RDW (reduced model) using R$^2$, adjusted R$^2$ and the root mean square error (RMSE). Finally, the predictive power of RDW for identifying patients with peak VO$_2$ ≤20 mL/kg/min and VE/VCO$_2$ slope ≥34 was quantified in terms of the area under the receiver operating characteristic (ROC) curve. Peak VO$_2$ ≤20 mL/kg/min and VE/VCO$_2$ slope ≥34 were one of the most commonly suggested dichotomous threshold values for poor prognosis in CHF.

All analyses were conducted using SPSS Statistics (version 18.0.0, IBM Corp., Armonk, NY, USA). A p value of less than 0.05 was considered statistically significant.

## RESULTS

### Baseline characteristics

Baseline characteristics according to tertile subgroups of RDW are summarized in Table 1 for patients with CHF and in Table 2 for healthy controls. For patients with CHF, the highest tertile group tended to be older, leaner and had a more severe New York Heart Association functional classification. Regarding laboratory findings, the highest tertile group had significantly lower average albumin levels compared to the lowest tertile group. Also, the highest tertile group had lower hemoglobin and higher uric acid. With regard to echocardiographic indices, LAVI was not different among three groups. However, S’ velocity was lower in the highest tertile group with a marginal significance. Lastly, estimated systolic pulmonary artery pressure was significantly elevated in the highest tertile group than the lowest tertile group (23.3±6.6 mm Hg vs. 24.7±4.7 mm Hg vs. 31.0±16.1 mm Hg, p=0.031).

In healthy controls, most subjects had RDW levels of the reference range (11.5-14.5%). However, eight subjects had higher RDW levels than the reference range. Age, hemoglobin, albumin levels, and E/E’ were significantly different among three groups in the healthy controls (Table 2).

### Cardiopulmonary exercise test data

When we analyzed the patients with CHF, exercise duration was significantly shorter in the highest tertile group compared with the lowest tertile group (Table 3). The RDW level had a graded relationship with maximal workload, peak VO$_2$ and VE/VCO$_2$ slope. The highest tertile group had highest VE/VCO$_2$ slope compared with the lowest tertile group. There were no differences in peak RER, baseline HR, peak HR, and HRR during exercise among the three groups (Table 3).

However, when we analyzed the healthy controls, exercise duration, maximal workload, and peak VO$_2$ were not different according to the RDW tertile groups. Only VE/VCO$_2$ slope, peak HR and HRR were significantly different according to the RDW tertile groups. Similar to the patients with CHF, the highest tertile group had highest VE/VCO$_2$ slope compared with the lowest tertile group in healthy con-
patients with CHF, peak VO\textsubscript{2} level was significantly correlated with age (β=-0.3, p=0.006), male gender (β=0.2, p=0.022), hemoglobin level (β=0.3, p=0.004), albumin level (β=-0.3, p=0.002), LVEF (β=0.3, p=0.004), E/E’ (β=0.4, p<0.001) and RDW tertile groups (Table 4). With regard to

**Table 1. Baseline Characteristics of Patients with CHF According to Tertile of RDW**

|                         | RDW tertile 1 (RDW<12.8) n=30 | RDW tertile 2 (12.8≤RDW≤13.2) n=30 | RDW tertile 3 (RDW>13.2) n=25 | p value |
|-------------------------|--------------------------------|-----------------------------------|--------------------------------|---------|
| Age (yrs)               | 51±10                          | 56±10                             | 55±10                          | 0.069   |
| Male                    | 27 (90)                        | 23 (77)                           | 18 (72)                        | 0.214   |
| BMI (kg/m\textsuperscript{2}) | 25.6±2.4                     | 26.6±4.1                         | 24.0±3.1                       | 0.018   |
| NYHA classification     |                                |                                   |                                | 0.115   |
| I                       | 22 (73)                        | 22 (73)                           | 11 (44)                        |         |
| II                      | 7 (23)                         | 8 (27)                            | 13 (52)                        |         |
| III                     | 1 (3)                          | 0 (0)                             | 1 (4)                          |         |
| Ischemic etiology       | 15 (50)                        | 16 (53)                           | 11 (44)                        | 0.786   |
| Underlying disease      |                                |                                   |                                |         |
| Hypertension            | 11 (37)                        | 13 (43)                           | 8 (32)                         | 0.682   |
| Diabetes mellitus       | 9 (30)                         | 6 (20)                            | 5 (20)                         | 0.583   |
| Medications             |                                |                                   |                                |         |
| Beta blockers           | 22 (73)                        | 24 (80)                           | 12 (48)                        | 0.030   |
| ACE inhibitors          | 8 (27)                         | 10 (33)                           | 7 (28)                         | 0.837   |
| ARBs                    | 16 (53)                        | 14 (47)                           | 14 (56)                        | 0.770   |
| CCBs                    | 4 (13)                         | 2 (7)                             | 5 (20)                         | 0.340   |
| Diuretics               | 14 (47)                        | 12 (40)                           | 18 (72)                        | 0.048   |
| Laboratory findings     |                                |                                   |                                |         |
| Hemoglobin (g/dL)       | 14.8±1.3                       | 14.5±1.4                          | 13.8±2.2                       | 0.063   |
| RDW (%)                 | 12.3±0.3                       | 13.0±0.1                          | 14.3±1.6                       | <0.001  |
| Sodium (mmol/L)         | 140±3                          | 141±2                             | 141±2                          | 0.722   |
| Uric acid (mg/dL)       | 5.8±1.0                        | 6.2±1.6                           | 6.1±1.5                        | 0.484   |
| Cholesterol (mg/dL)     | 161±36                         | 162±30                            | 154±32                         | 0.677   |
| eGFR (mL/min/1.73 m\textsuperscript{2}) | 82±15                      | 77±14                             | 76±16                          | 0.232   |
| Albumin (g/dL)          | 4.5±0.4                        | 4.3±0.2                           | 4.2±0.3                        | 0.002   |
| Ln hsCRP (mg/L)         | 0.27±1.24                      | 0.58±1.10                         | 0.44±1.17                      | 0.654   |
| Echocardiographic indices|                                |                                   |                                |         |
| LVEF (%)                | 39±9                            | 38±11                             | 36±11                          | 0.511   |
| LVEDD (mm)              | 58±8                            | 60±10                             | 60±8                           | 0.758   |
| LVESD (mm)              | 47±9                            | 47±11                             | 48±9                           | 0.853   |
| LAVI (mL/m\textsuperscript{2}) | 29±10                      | 31±7                              | 43±23                          | 0.002   |
| E velocity (cm/s)       | 0.65±0.19                      | 0.57±0.19                         | 0.74±0.31                      | 0.030   |
| S’ (cm/s)               | 5.4±1.4                        | 4.8±1.5                           | 4.6±1.7                        | 0.159   |
| E’ (cm/s)               | 6.3±2.8                        | 4.4±1.4                           | 4.6±1.6                        | 0.003   |
| A’ (cm/s)               | 7.8±1.8                        | 7.1±1.7                           | 6.0±2.4                        | 0.007   |
| E/E’                    | 12.0±5.5                       | 13.9±6.9                          | 16.5±10.2                      | 0.110   |
| Systolic PAP (mm Hg)    | 23.3±6.6                       | 24.7±4.7                          | 31.0±16.1                      | 0.031   |

RDW, red cell distribution width; BMI, body mass index; NYHA, New York Heart Association; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; PAP, pulmonary artery pressure; CHF, chronic heart failure; LAVI, left atrial volume index; hsCRP, high-sensitivity C-reactive protein.
Values are mean±SD or number (%).
RDW and Ventilatory Inefficiency in CHF

Table 2. Baseline Characteristics of Healthy Controls According to Tertile of RDW

| RDW tertile 1 (RDW<12.7) | RDW tertile 2 (12.7≤RDW≤13.0) | RDW tertile 3 (RDW>13.0) | p value |
|--------------------------|-------------------------------|--------------------------|---------|
| Age (yrs)                | 41±17                         | 44±16                    | 50±16   | 0.052 |
| Male                     | 21 (58)                       | 20 (59)                  | 13 (35) | 0.070 |
| BMI (kg/m²)              | 22.1±3.1                      | 22.7±3.7                 | 22.1±3.3| 0.724 |
| Laboratory findings      |                               |                          |         |
| Hemoglobin (g/dL)        | 14.7±1.4                      | 14.3±1.1                 | 13.6±2.2| 0.017 |
| RDW (%)                  | 12.3±0.3                      | 12.8±0.1                 | 14.2±2.7| <0.001 |
| Sodium (mmol/L)          | 141±2                         | 141±2                    | 141±2   | 0.977 |
| Uric acid (mg/dL)        | 4.8±1.0                       | 4.9±1.2                  | 4.9±1.5 | 0.984 |
| Cholesterol (mg/dL)      | 183±35                        | 189±29                   | 188±43  | 0.784 |
| eGFR (mL/min/1.73 m²)    | 98±14                         | 101±15                   | 92±19   | 0.077 |
| Albumin (g/dL)           | 4.5±0.2                       | 4.3±0.2                  | 4.3±0.3 | 0.011 |
| Echocardiographic indices|                               |                          |         |
| LVEF (%)                 | 66±6                          | 67±5                     | 66±6    | 0.915 |
| LVEDD (mm)               | 47±4                          | 47±3                     | 48±4    | 0.510 |
| LVESD (mm)               | 31±3                          | 31±3                     | 32±3    | 0.514 |
| LAVI (mL/m²)             | 21±6                          | 20±5                     | 23±6    | 0.117 |
| E velocity (cm/s)        | 0.64±0.13                     | 0.64±0.13                | 0.68±0.15| 0.325 |
| A velocity (cm/s)        | 0.50±0.15                     | 0.56±0.13                | 0.58±0.18| 0.073 |
| E/E'                     | 7.0±1.6                       | 8.0±1.7                  | 8.4±2.3 | 0.001 |

RDW, red cell distribution width; BMI, body mass index; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LAVI, left atrial volume index.

Values are mean±SD or number (%).

Table 3. Cardiopulmonary Exercise Testing of Patients with CHF and Healthy Controls

| RDW tertile 1 | RDW tertile 2 | RDW tertile 3 | p value |
|---------------|---------------|---------------|---------|
| Patients with CHF |               |               |         |
| Exercise duration (s) | 739±167       | 636±191       | 534±170 | <0.001 |
| Max. workload (METs) | 8.1±1.8       | 7.1±1.7       | 6.2±1.5 | <0.001 |
| Peak VO₂ (mL/kg/min) | 28.3±6.2      | 24.9±5.9      | 21.7±5.2| <0.001 |
| VE/VCO₂ slope | 25.3±3.6      | 27.8±4.6      | 31.0±8.4| 0.002 |
| Peak RER     | 1.16±0.14     | 1.13±0.11     | 1.08±0.13| 0.096 |
| Baseline HR (bpm) | 78±20         | 77±10         | 77±16   | 0.994 |
| Peak HR (bpm) | 155±30        | 145±18        | 144±25  | 0.205 |
| HRR (bpm)    | 77±24         | 68±17         | 67±24   | 0.147 |
| Healthy controls |             |               |         |
| Exercise duration (s) | 806±177       | 810±133       | 746±195 | 0.212 |
| Max. workload (METs) | 9.2±2.2       | 9.2±1.9       | 8.6±2.1 | 0.394 |
| Peak VO₂ (mL/kg/min) | 32.2±7.6      | 32.2±6.7      | 30.2±7.3| 0.381 |
| VE/VCO₂ slope | 27.6±3.3      | 27.5±3.7      | 29.6±4.5| 0.045 |
| Peak RER     | 1.13±0.09     | 1.15±0.09     | 1.10±0.12| 0.074 |
| Baseline HR (bpm) | 74±12         | 72±12         | 72±11   | 0.588 |
| Peak HR (bpm) | 166±22        | 169±18        | 155±25  | 0.025 |
| HRR (bpm)    | 92±20         | 97±14         | 84±24   | 0.027 |

Max, maximal; RER, respiratory exchange ratio; HR, heart rate; HRR, heart rate reserve; CHF, chronic heart failure; RDW, red cell distribution width; MET, metabolic equivalent.

Values are mean±SD.
For prediction of both peak VO\(_2\) and VE/VCO\(_2\) slope, the R\(^2\) and adjusted R\(^2\) of the full model was greater than those of the reduced model and the RMSE of the full model was less than that of the reduced model (Table 5). ROC curve indicated a good power of RDW in identifying patients with peak VO\(_2\) ≤20 mL/kg/min and VE/VCO\(_2\) slope ≥34 [area under the curve 0.717, 95% confidence interval (CI)=0.556-0.878 for peak VO\(_2\) and AUC 0.858, 95% CI=0.747-0.970 for VE/VCO\(_2\) slope] (Fig. 1). The optimal cutoff value of RDW for predicting peak VO\(_2\) ≤20 mL/kg/min and VE/VCO\(_2\) slope ≥34 was 13.6% (sensitivity 53%, specificity 89%) and 13.4% (sensitivity 75%, specificity 82%), respectively.

### Table 4. Univariate and Multivariate Analysis for Peak VO\(_2\) and VE/VCO\(_2\) Slope

|                     | Univariate | Multivariate |
|---------------------|------------|--------------|
|                     | β (SE)     | p value      | β (SE)     | p value      |
| **Peak VO\(_2\)**  |            |              |            |              |
| Patients with CHF   |            |              |            |              |
| RDW tertile 2       | -0.030 (1.45) | 0.783 | -0.094 (1.45) | 0.393 |
| RDW tertile 3       | -0.353 (1.42) | 0.001 | -0.247 (1.65) | 0.035 |
| Healthy controls    |            |              |            |              |
| RDW tertile 2       | 0.070 (1.50) | 0.471 | 0.057 (1.21) | 0.499 |
| RDW tertile 3       | -0.136 (1.46) | 0.164 | 0.016 (1.45) | 0.874 |
| **VE/VCO\(_2\) slope** |            |              |            |              |
| Patients with CHF   |            |              |            |              |
| RDW tertile 2       | -0.063 (1.28) | 0.566 | 0.183 (1.29) | 0.120 |
| RDW tertile 3       | 0.435 (1.21) | ≤0.001 | 0.366 (1.46) | 0.004 |
| Healthy controls    |            |              |            |              |
| RDW tertile 2       | -0.121 (0.85) | 0.215 | -0.025 (0.92) | 0.805 |
| RDW tertile 3       | 0.240 (0.81) | 0.013 | 0.056 (1.09) | 0.646 |

CHF, chronic heart failure; RDW, red cell distribution width; SE, standard error. Adjusted for age, sex, body mass index, hemoglobin, albumin, estimated glomerular filtration rate, left ventricular ejection fraction and E/E’. RDW tertile 1 as a reference.

### Table 5. Comparison of a Model with RDW (Full Model) and a Model without RDW (Reduced Model)

| Goodness of fit statistics | Peak VO\(_2\) | VE/VCO\(_2\) slope |
|----------------------------|--------------|-------------------|
|                            | R\(^2\)      | Adjusted R\(^2\) | RMSE    | R\(^2\)      | Adjusted R\(^2\) | RMSE    |
| Model 1 (full model)       | 0.457        | 0.376             | 5.110   | 0.387        | 0.295             | 4.522   |
| Model 2 (reduced model)    | 0.419        | 0.352             | 5.208   | 0.305        | 0.224             | 4.743   |

RMSE, root mean square error; RDW, red cell distribution width.

Model 1: adjusted for age, male gender, body mass index, hemoglobin, albumin, estimated glomerular filtration rate, left ventricular ejection fraction, E/E’. RDW tertile. Model 2: adjusted for age, male gender, body mass index, hemoglobin, albumin, estimated glomerular filtration rate, left ventricular ejection fraction, E/E’.

Ventilatory inefficiency for patients with CHF, VE/VCO\(_2\) slope was also significantly correlated with age (β=0.2, p=0.033), body mass index (BMI) (β=0.3, p=0.007), hemoglobin level (β=0.3, p=0.015), albumin level (β=0.3, p=0.002), LVEF (β=0.4, p=0.001), E/E’ (β=0.4, p=0.001) and RDW tertile groups (Table 4).

However, notably in healthy controls, peak VO\(_2\) level and VE/VCO\(_2\) slope did not significantly correlated with RDW tertile groups (Table 4).

### Independent predictors for peak VO\(_2\) and VE/VCO\(_2\) slope

Multiple linear regression analysis demonstrated an independent association between peak VO\(_2\) and RDW tertile groups (Table 4). BMI and E/E’ were other independent predictors of peak VO\(_2\). Similarly, an independent association between VE/VCO\(_2\) slope and RDW tertile groups was observed (Table 4). Also, E/E’ was another independent predictor of VE/VCO\(_2\) slope.

For prediction of both peak VO\(_2\) and VE/VCO\(_2\) slope, the R\(^2\) and adjusted R\(^2\) of the full model was greater than those of the reduced model and the RMSE of the full model was less than that of the reduced model (Table 5). ROC curve indicated a good power of RDW in identifying patients with peak VO\(_2\) ≤20 mL/kg/min and VE/VCO\(_2\) slope ≥34 [area under the curve 0.717, 95% confidence interval (CI)=0.556-0.878 for peak VO\(_2\) and AUC 0.858, 95% CI=0.747-0.970 for VE/VCO\(_2\) slope] (Fig. 1). The optimal cutoff value of RDW for predicting peak VO\(_2\) ≤20 mL/kg/min and VE/VCO\(_2\) slope ≥34 was 13.6% (sensitivity 53%, specificity 89%) and 13.4% (sensitivity 75%, specificity 82%), respectively.

### DISCUSSION

The principal findings of this study are that 1) higher RDW is related to lower exercise capacity with lower peak VO\(_2\).
and ventilatory inefficiency with higher VE/VCO\textsubscript{2} slope in patients with CHF, 2) in contrast to patients with CHF, RDW is not related to exercise capacity or ventilatory inefficiency in healthy controls, and 3) RDW is an independent predictor of peak VO\textsubscript{2} and VE/VCO\textsubscript{2} slope when controlling for other confounding variables in patients with HF.

Among various prognostic markers for CHF, increased RDW has emerged as an additional predictor of poor outcomes, especially for patients with HF. It is known that RDW is typically high when red cell production is not effective, such as iron deficiency, vitamin B\textsubscript{12} or folate deficiency.\textsuperscript{11,21-23} Although the reasons for higher RDW and poor prognosis in HF is not fully understood, some explanations have been suggested. Persistent inflammation has been known to predict progressive illness, cardiovascular mortality, and death in HF.\textsuperscript{9} Systemic inflammatory response could affect iron metabolism or bone marrow dysfunction. Pro-inflammatory cytokines have been found to inhibit erythropoietin-induced erythrocyte maturation and proliferation and down regulate erythropoietin receptor expression, which is associated with increases in RDW.\textsuperscript{21} Also, RDW may serve as an integrative measure of multiple processes simultaneously occurring in CHF, such as kidney dysfunction, hepatic congestion, and nutritional deficiencies.\textsuperscript{2,3} Therefore, increased RDW in CHF might be representative of chronic inflammation, and this can lead to poor prognosis in patients with CHF who have higher RDW.

Chronic inflammation plays a key role in HF pathophysiology, and it is known to be more pronounced in advanced disease stages.\textsuperscript{24,25} Also, Thierer, et al.\textsuperscript{18} reported that the functional capacity measured by the 6-min walk test was related to the degree of inflammatory activity and catabolism. The relationship between chronic inflammation and exercise capacity is well established not only in CHF but also in respiratory diseases such as chronic obstructive pulmonary disease and cystic fibrosis.\textsuperscript{26} Chronic inflammation results in anemia, muscle mass loss, and is associated with decreased lung volumes.\textsuperscript{18,27} Therefore, it is plausible that chronic inflammation may play an important pathophysiological role in exercise intolerance and ventilatory inefficiency in patients with CHF. In the present study, we demonstrate that increased RDW, which can represent chronic inflammation, is associated with exercise intolerance and ventilatory inefficiency in patients with CHF. Increased RDW can be a further indication of more severe HF and is associated with ventilatory inefficiency as well as exercise intolerance. Interestingly, when we analyzed the healthy controls, RDW was higher than patients with CHF. Furthermore, RDW did not have significant correlation with peak VO\textsubscript{2} or VE/VCO\textsubscript{2} slope. Thus, these data can further support our suggestion that increased RDW in the patients with CHF as a result of inflammation could be associated with exercise intolerance and ventilatory inefficiency.

Interestingly, despite the selection criteria of the healthy controls without any cardiovascular risk factors such as hypertension, diabetes or dyslipidemia, we found that the highest tertile groups in the healthy controls were older and had lower hemoglobin and albumin levels. Thus, the above mechanisms could be applied to the healthy controls as well.

Consistent with our findings, Van Craenenbroeck, et al.\textsuperscript{28} previously reported that higher RDW was negatively correlated with peak VO\textsubscript{2} and positively correlated with VE/VCO\textsubscript{2}.
slope. However, in contrast to our findings, higher RDW was an independent predictor of peak VO$_2$ only and not independently related to VE/VCO$_2$ slope. This discrepancy is likely attributable to the differing patients’ characteristics enrolled in each study. The patients enrolled in our study were relatively younger and had less severe HF symptoms. Also, exercise capacities along with LV systolic and diastolic function were much better in this study compared to those in the previous report. RDW cutoff values, 13.6% and 13.4% for predicting peak VO$_2 \leq 20$ mL/kg/min and VE/VCO$_2$ slope $\geq 34$ in our study were also comparable with the previous study, the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity program (CHARM). In the CHARM study, adverse events for death or hospitalization were increased with patients with RDW greater than 14.7%. Also, we previously reported that RDW for prediction of elevated LV filling pressure, E/E’ $>15$, was greater than 13.5%.  

Moreover, these results confirmed our previous findings that reported a significant relationship between increased RDW and LV filling pressure, represented by increased E/E’, although the previous study subjects were acute decompensated heart failure patients. Increased E/E’ or increased systolic pulmonary artery pressure with higher RDW might be another explanation why CHF patients with higher RDW have exercise intolerance and ventilatory inefficiency. Our findings are consistent with previous studies that report LV diastolic dysfunction as being more likely to present a poorer CPET response (higher VE/VCO$_2$ slope, lower peak VO$_2$). Interestingly, in the present study, both peak VO$_2$ and VE/VCO$_2$ slope were significantly correlated with E/E’ and LVEF, but only E/E’ remained as an independent predictor for peak VO$_2$ and VE/VCO$_2$ slope. Thus, in line with these findings, hemodynamic stress to the heart in CHF also could be an important factor for exercise intolerance and ventilatory inefficiency.

Several potential limitations of the present study need consideration. First, due to the cross sectional design of this study we cannot define, but only suggest, a causal relationship between RDW levels and both exercise capacity and ventilatory inefficiency. Second, the present study included mostly younger patients with mild CHF. Extrapolations of this association to CHF of higher clinical severity should be made with caution. Third, assessment of inflammatory stress, by measuring other proinflammatory cytokines could have identified a possible link between inflammation, exercise intolerance, and high RDW. Unfortunately, these data were not available in our study. Fourth, there was a time interval between the laboratory test (RDW) and CPET, although we excluded patients whose interval was longer than 3 months.

In conclusion, higher RDW is independently related to exercise intolerance and ventilatory inefficiency in patients with CHF, but not in healthy controls. Based on our findings in measuring RDW, which is inexpensive and easily performed, it might help predict functional capacity and ventilatory efficiency in CHF patients. Further investigations are needed to determine whether increased RDW plays a pathophysiological role in exercise intolerance or ventilatory inefficiency in CHF patients.

**REFERENCES**

1. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
2. Chua TP, Ponikowski P, Harrington D, Anker SD, Webb-Peploe K, Clark AL, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol 1997;29:1585-90.
3. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000;101:2803-9.
4. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007;50:40-7.
5. Al-Najjar Y, Goode KM, Zhang J, Cleland JG, Clark AL. Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure. Eur J Heart Fail 2009;11:1155-62.
6. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J 2009;158:659-66.
7. Oh J, Kang SM, Won H, Hong N, Kim SY, Park S, et al. Prognostic value of change in red cell distribution width 1 month after discharge in acute decompensated heart failure patients. Circ J 2012;76:109-16.
8. Hong N, Oh J, Kang SM, Kim SY, Won H, Youn JC, et al. Red blood cell distribution width predicts early mortality in patients with acute dyspnea. Clin Chim Acta 2012;413:992-7.
9. Allen LA, Felker GM, Mehta MR, Chiong JR, Dunlap SH, Ghali JK, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail 2010;16:230-8.
10. Chiari MM, Bagnoli R, De Luca PD, Monti M, Rampoldi E, Cuni etti E. Influence of acute inflammation on iron and nutritional status indexes in older inpatients. J Am Geriatr Soc 1995;43:767-71.
11. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesaniparinone.
trial (VEST). Circulation 2001;103:2055-9.

12. Uthamalingam S, Kandala J, Daley M, Patwardhan E, Capodilupo R, Moore SA, et al. Serum albumin and mortality in acutely decompensated heart failure. Am Heart J 2010;160:1149-55.

13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.

14. Quinones MA, Waggerer AD, Reduto LA, Nelson JG, Young JB, Winters WL Jr, et al. A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation 1981;64:744-53.

15. Folland ED, Parisi AF, Moynihan PF, Jones DR, Feldman CL, Tow DE. Assessment of left ventricular ejection fraction and volumes by real-time, two-dimensional echocardiography. A comparison of cineangiographic and radionuclide techniques. Circulation 1979;60:760-6.

16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988;12:426-40.

17. Thierer J, Acosta A, Vainstein N, Sultan M, Francesia A, Marino J, et al. Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study). Am J Cardiol 2010;105:977-83.

18. Gardin JM, Leifer ES, Fleg JL, Whellan D, Kokkinos P, Leblanc MH, et al. Relationship of Doppler-Echocardiographic left ventricular diastolic function to exercise performance in systolic heart failure: the HF-ACTION study. Am Heart J 2009;158(4 Suppl): S45-52.

19. Weber KT, Janicki JS. Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 1985;55:22A-31A.

20. Karnad A, Poskitt TR. The automated complete blood cell count. Use of the red blood cell volume distribution width and mean platelet volume in evaluating anemia and thrombocytopenia. Arch Intern Med 1985;145:1270-2.

21. Thompson WG, Meola T, Lipkin M Jr, Freedman ML. Red cell distribution width, mean corpuscular volume, and transferrin saturation in the diagnosis of iron deficiency. Arch Intern Med 1988;148:2128-30.

22. Aslan D, Gümrük F, Gürgey A, Altay C. Importance of RDW value in differential diagnosis of hypochrome anemias. Am J Hematol 2002;69:31-3.

23. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart 2004;90:464-70.

24. Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, et al. Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J 2012;53:91-8.

25. van de Weert-van Leeuwen PB, Slieker MG, Hulzebos HJ, Kruitwagen CL, van der Ent CK, Arets HG. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur Respir J 2012;39:893-8.

26. Gläser S, Ittermann T, Koch B, Völzke H, Wallaschofski H, Nauck M, et al. Airflow limitation, lung volumes and systemic inflammation in a general population. Eur Respir J 2012;39:29-37.

27. Van Craenenbroeck EM, Pelle AJ, Beckers PJ, Possemiers NM, Ramakers C, Vrints CJ, et al. Red cell distribution width as a marker of impaired exercise tolerance in patients with chronic heart failure. Eur J Heart Fail 2012;14:54-60.

28. Oh J, Kang SM, Hong N, Choi JW, Lee SH, Park S, et al. Relation between red cell distribution width with echocardiographic parameters in patients with acute heart failure. J Card Fail 2009;15:517-22.

29. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Pinkstaff S, et al. Echocardiography with Tissue Doppler Imaging and cardiopulmonary exercise testing in patients with heart failure: a correlative and prognostic analysis. Int J Cardiol 2010;143:323-9.